Nerandomilast

Nerandomilast
Clinical data
Trade names	Jascayd
Other names	BI-1015550, BI 1015550
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a625107
License data	US DailyMed: Nerandomilast;
Drug class	Phosphodiesterase-4 inhibitor
ATC code	L04AA61 (WHO) ;
Legal status
Legal status	US: ℞-only; CN: Rx-only;
Identifiers
CAS Number	1423719-30-5;
PubChem CID	166177189;
DrugBank	DB18237;
ChemSpider	129160248;
UNII	I5DGT51IB8;
KEGG	D12975;
Chemical and physical data
Formula	C20H25ClN6O2S
Molar mass	448.97 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(C1)(CO)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(C=N5)Cl;
	InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1; Key:UHYCLWAANUGUMN-SSEXGKCCSA-N;

Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It is a phosphodiesterase 4 (PDE4) inhibitor. It is taken by mouth.

Side effects include diarrhea, decreased weight, decreased appetite, and nausea.

Nerandomilast was approved for medical use in the United States in October 2025.